Skip to main content

Table 6 Major treatment and prognosis for CH and CH post CI [n (%)]

From: Influences of blood lipids on the occurrence and prognosis of hemorrhagic transformation after acute cerebral infarction: a case-control study of 732 patients

Treatment and prognosis Group A (n = 628) Group B (n = 104) P
rTPA     0.403
  No 550 (87.6) 88 (84.6)  
  Yes 78 (12.4) 16 (15.4)  
Argatroban     0.363
  No 521 (83.0) 90 (86.5)  
  Yes 107 (17.0) 14 (13.5)  
LMWH     0.059*
  No 606 (96.5) 96 (92.3)  
  Yes 22 (3.5) 8 (7.7)  
Warfarin     0.536*
  No 624 (99.4) 103 (99.0)  
  Yes 4 (0.6) 1 (1.0)  
D-Anti-PLT     0.852
  0, no/single 290 (46.2) 47 (45.2)  
  1, double 338 (53.8) 57 (54.8)  
SILL     0.744
  0, no 443 (70.5) 75 (72.1)  
  1, ILL 185 (29.5) 29 (27.9)  
  1. rTPAvein thrombolysis with recombinant human tissue plasminogen activator. LMWH: Low-molecular-weight heparin. D-anti-PLT (platelets): Aspirin 100 mg or 300 mg + clopidogrel hydrogen sulfate 75 mg; SILL: Intensive lipid-lowering statins. *: Fisher’s exact test (2-sided)
\